RECOMBINANT ONCOLYTIC VIRUSES FOR CANCER THERAPY

The disclosure provides a recombinant oncolytic poxvirus including vaccinia virus comprising one or more inactivated immunomodulatory gene selected from NIL, K1L, K3L, A46R, and/or A52R, optionally further comprising inactivated TK and/or VGF genes. The disclosure also provides methods and for the u...

Full description

Saved in:
Bibliographic Details
Main Authors HO, Tiffany, Yun-Yee, STOJDL, David, Francis, MCCART, Judith, Andrea
Format Patent
LanguageEnglish
French
Published 05.04.2018
Subjects
BASIC ELECTRIC ELEMENTS
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
DERIVATIVES THEREOF
ELECTRICITY
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSIONOF CHEMICAL INTO ELECTRICAL ENERGY
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
SUGARS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The disclosure provides a recombinant oncolytic poxvirus including vaccinia virus comprising one or more inactivated immunomodulatory gene selected from NIL, K1L, K3L, A46R, and/or A52R, optionally further comprising inactivated TK and/or VGF genes. The disclosure also provides methods and for the use of these recombinant oncolytic poxvirus in oncolytic virotherapy. Also provided in the disclosure are vector constructs for generating recombinant oncolytic poxviruses including for example vaccinia viruses that have one or more inactivated immunomodulatory genes. L'invention concerne un poxvirus oncolytique recombiné comprenant un virus de la vaccine comprenant un ou plusieurs gènes immunomodulateurs inactivés choisis parmi NIL, K1L, K3L, A46R et/ou A52R, comprenant en outre éventuellement des gènes TK et/ou VGF inactivés. L'invention concerne également des procédés et l'utilisation de ces poxvirus oncolytiques recombinés dans une virothérapie oncolytique. L'invention concerne également des constructions de vecteur permettant de générer des poxvirus oncolytiques recombinés comprenant, par exemple, des virus de la vaccine qui ont un ou plusieurs gènes immunomodulateurs inactivés.
Bibliography:Application Number: WO2017CA51171